AVXL
ANAVEX LIFE SCIENCES CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.27
+5.42%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.24
From 52W high−83.07%
Volume499825.00
Market cap$117.26M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.24
From 52W high
−83.07%
Volume
499825.00
Market cap
$117.26M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
28.1
MomentumView details →
1D Return
+5.42%
YTD Return
−65.58%
SummaryUpdated Jun 1, 2026
Anavex Life Sciences Corp. (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in New York. The company has been publicly traded since 2006 and focuses exclusively on developing treatments for central nervous system (CNS) diseases, particularly neurodegenerative and neuropsychiatric conditions. Anavex has built its pipeline around sigma receptor modulators, with its lead drug candidate <b>blarcamesine</b> (ANAVEX 2-73) currently in Phase III trials for Alzheimer's disease and having recently received marketing authorization application acceptance from the European Medicines Agency.
Similar companies
Latest newsMore news →
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit had been filed against ANAVEX LIFE SCIENCES CORP. on behalf of investors who acquired its securities during the class period.19h agoAdrian Senderowicz resigned from ANAVEX LIFE SCIENCES CORP.'s board of directors.2d agoGautam Patel resigned as a member of ANAVEX LIFE SCIENCES CORP.'s Audit Committee.2d ago